Citations

Clear

71 citation(s) found for "Hassoun, P M".

Glaucoma Progression and Development Following Secondary Intraocular Lens Surgery
Wang, Kenny Y. , Hassoun, Mohamad Rani , Sharma, Kannan

Mayo Clinic

Ophthalmic Surgery, Lasers and Imaging Retina | October 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.3928/23258160-20260819-03 | PMID 42823090 Get It

Background and Objective: This study aimed to investigate glaucoma progression following secondary intraocular lens (SIOL) implantation by surgical approach. Patients and Methods: This was a single-center retrospective study of 440 eyes that received SIOL implantation, including scleral-sutured, scleral-fixated, anterior chamber, and sulcus-fixated. Glaucoma progression was defined as new diagnosis, procedure for intraocular pressure (IOP) control, or IOP elevation ≥ 24 mmHg or ≥ 5 mmHg above baseline requiring additional medications. Risk factors were assessed using multivariable analysis. Results: Mean age at surgery was 71.3 years and 29.3% of patients had prior glaucoma. Overall, 33.2% developed glaucoma progression. Prior glaucoma (hazard ratio 2.08 [95% CI 1.47–2.94], P < .001) and cystoid macular edema (1.63 [1.06–2.52], P = .026) were associated with glaucoma progression on multivariable analysis. There was no difference in glaucoma progression between scleral-sutured, scleral-fixated, anterior chamber, or sulcus-fixated implantation techniques. Conclusion: Our results suggest that surgeons should use their preferred SIOL implantation technique but closely monitor postoperative IOP.
Endophthalmitis Following Pars Plana Vitrectomy: An IRIS® Registry Study
Hassoun, Mohamad Rani , Wang, Kenny Y. , Kim, B. Michelle, Blumenfeld, Sophia, Lum, Flora, Starr, Matthew R. , Lum, Flora

Mayo Clinic

Retina | September 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/iae.0000000000005015 | PMID 42765869 Get It

Purpose: The purpose of this study is to characterize the clinical features, management strategies, and outcomes of endophthalmitis cases following pars plana vitrectomy using data from the American Academy of Ophthalmology (Academy) IRIS ® Registry (Intelligent Research in Sight). Methods: This is a retrospective cohort study of eyes that developed endophthalmitis following pars plana vitrectomy between 2013 and 2022. Data was collected from the Academy IRIS Registry. This study analyzed differences in visual acuity, intraocular pressure, rates of evisceration and enucleation, and rates of rhegmatogenous retinal detachment following endophthalmitis diagnosis. Results: A total of 1,223,777 unique eyes underwent a PPV during the study period, with 1,275 eyes meeting the inclusion criteria. The median time from pars plana vitrectomy to endophthalmitis diagnosis was 10 days. The majority of eyes (80.9%) were managed with intravitreal antibiotics alone, without a repeat pars plana vitrectomy. Long-term visual acuity, intraocular pressure, cup-to-disc ratio, and rate of evisceration or enucleation did not differ significantly between treatment groups. However, eyes that underwent the initial pars plana vitrectomy for retinal detachment repair had poorer long-term vision and higher rates of retinal detachment following endophthalmitis. Overall, 16.1% of eyes required evisceration or enucleation in this cohort. Conclusions: Despite its rarity, post-pars plana vitrectomy endophthalmitis can cause significant morbidity and even globe loss. There were no significant differences observed between eyes that were treated with intravitreal tap and inject versus repeat pars plana vitrectomy.
Bachmann's bundle pacing: toward physiologic atrial activation
Zhang, Ke, Chaaya, Mary Lyn Bou, Hassoun, Talia, Tan, Nicholas Y., Ezzeddine, Fatima M., Tan, Nicholas Y. , Ezzeddine, Fatima M.

Mayo Clinic

Frontiers in Cardiovascular Medicine | July 29, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fcvm.2026.1895174 | PMID 42591967 Get It

Bachmann's bundle (BB) pacing is an emerging physiological atrial pacing strategy designed to preserve interatrial conduction and coordinated atrial activation. Conventional right atrial appendage pacing may produce non-physiological activation, contributing to atrial dyssynchrony, impaired left atrial function, and increased risk of atrial fibrillation. Because BB is the predominant pathway for right-to-left atrial conduction, targeted BB pacing can shorten the P-wave duration and improve atrial synchrony. Recent fluoroscopic, electrogram-guided, and P-wave morphology criteria have improved confirmation of BB capture. Available studies suggest that BB pacing is feasible and generally safe, with potential benefits in reducing the burden of atrial arrhythmias. However, the long-term clinical outcomes remain uncertain. Larger prospective studies are needed to standardize BB capture criteria, define optimal patient selection, and assess long-term outcomes.
Platelet-Derived Exosome Product Prolongs Stem Cell-Derived β-Cell Graft Survival and Is Associated with Reduced Nk Cell Infiltration and Immunomodulation
Khashim, Zenith , Shrestha, Swikriti , Hassoun, Shaimaa, Law, Ethan W. , Schornack, Anna Marie R , Lacap, Jessica, Weigel, G. , Jennings, Lauren , Becher, Laura, Paradise, Christopher R. , Behfar, Atta, Fairweather, DeLisa , Peterson, Quinn P. , Beetler, Danielle J. , Weigel, Gabe J , Jennings, Lauren T. , van Wijnen, Andre J , Fairweather, DeLisa , Peterson, Quinn , Schornack, Anna Marie , Law, Ethan W , Hassoun, Shaimaa, Becher, Laura , Behfar, Atta

Mayo Clinic

Cells | July 29, 2026 | Volume: 15 | Issue: 15 | Pages: 1367

10.3390/cells15151367 | PMID 42587776 Get It

Stem cell-derived β (SC-β) cells are a promising therapy for type 1 diabetes (T1D), but their long-term efficacy is limited by immune-mediated graft rejection. Platelet-derived exosome product (PEP) has emerged as a novel immunomodulatory agent, although its effect on SC-β cell xenograft rejection remains unclear. Here, we evaluated PEP in stimulated human peripheral blood mononuclear cells (PBMCs) and in an immunocompetent mouse model of SC-β cell transplantation under the kidney capsule. Immune-related gene expression was assessed by quantitative PCR, immune cell infiltration by immunofluorescence, and graft function by circulating human insulin. In vitro, PEP reduced NK-cell-associated gene expression, including NK1.1, EOMES, and KLRK1, and increased IL-10 expression. In vivo, untreated SC-β cell xenografts showed progressive immune infiltration and loss of detectable human insulin by day 14, whereas PEP-treated grafts retained detectable insulin through day 14 across co-transplantation, pretreatment, and systemic administration strategies. PEP co-transplantation delayed, but did not prevent, xenograft rejection, with graft loss observed by day 21. This delay was associated with reduced NK1.1+ cell infiltration and lower expression of selected inflammatory and rejection-associated markers, including NK1.1, Nos2, and Nlrp3. These findings suggest that PEP modulates graft-associated immune responses and may serve as an adjunct immunomodulatory strategy for stem cell-based therapies for type 1 diabetes. Further studies are needed to evaluate sustained graft durability, safety, and translational efficacy.
Endotypes of Vascular Health Predict Transplantation‐Free Survival in Pulmonary Hypertension
Farha, Samar , Hu, Bo , Chen, Ruoying, Barnard, John , Comhair, Suzy , Heresi, Gustavo A. , Parambil, Joseph, Tonelli, Adriano R. , Beck, Gerald J. , Rosenzweig, Erika B. , Finet, J. Emanuel , Grünig, Gabriele , Hill, Nicholas S. , Jellis, Christine , Park, Margaret , Rischard, Franz P., Olman, Mitchell A. , Erzurum, Serpil C. , Dweik, Raed A. , Group, the PVDOMICS Study, Heresi, Gustavo , Tonelli, Adriano , Beck, Gerald J , Rosenzweig, Erika B , DuBrock, Hilary M , Finet, J Emanuel , Frantz, Robert P , Hassoun, Paul M , Hemnes, Anna , Hill, Nicholas S , Horn, Evelyn M , Jellis, Christine L , Leopold, Jane A , Park, Margaret M , Simpson, Catherine E , Tang, W H Wilson , Erzurum, Serpil C , Dweik, Raed A , Barnard, John , Comhair, Suzy , Hu, Bo , Chen, Ruoying, Parambil, Joseph G. , DuBrock, Hilary M. , Frantz, Robert P. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Simpson, Catherine E. , Tang, W.H. Wilson , Group, The PVDOMICS Study

Mayo Clinic

Journal of the American Heart Association | July 17, 2026 | Volume: 15 | Issue: 14 | Pages: No page available

10.1161/jaha.125.048795 | PMID 42466490 Get It

Background The current classification of pulmonary hypertension (PH), based largely on expert opinion, has limitations in prognostication and guiding therapies. We hypothesize that novel PH clusters that predict survival will reveal mechanistic phenotypes associated with biomarkers of vascular health across all PH groups. Methods We first identify novel PH clinical clusters by performing unsupervised clustering analysis on the CC‐PH (Cleveland Clinic PH) registry (N=1529). We develop classification models to predict the new PH clusters and then apply them to the multicenter PVDOMICS (Pulmonary Vascular Diseases Phenomics) cohort (N=853) for validation. We compare transplantation‐free survival across the new PH clusters. We quantify metabolites of the arginine‐nitric oxide pathway and D‐dimer levels and calculate global arginine bioavailability (arginine/[ornithine+citrulline]) to assess endothelial function and activation in the new clusters and link these biomarkers to clinical outcomes. Results Clustering analysis identify 3 clear clusters in CC ‐ PH that are validated in PVDOMICS and outperform conventional classifications in predicting transplantation‐free survival. The phenotype associated with the worst survival is characterized by reduced lung diffusion capacity, decreased arginine bioavailability and nitrate levels, and elevated D‐dimer levels, consistent with loss of pulmonary microcirculation and endothelial dysfunction. Conclusions We identify new informative PH phenotypes associated with mortality and defined by biomarkers of endothelial function and activation. Loss of endothelial health and pronounced pulmonary vascular rarefication contribute more substantially to mortality across the spectrum of PH than right heart function. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02980887.
Metabolomic Network Analysis Reveals Reorganization of Lipid and Steroid Programs Linked to Right Ventricular-Pulmonary Vascular Function in Pulmonary Hypertension
Clinton, Ivor, Coursen, Julie , Rosen, Darin , Suresh, Karthik , Balasubramanian, Aparna , Kolb, Todd M. , Damico, Rachel L. , Mathai, Stephen C. , Hsu, Steven , Mukherjee, Monica , Finet, J. Emanuel , Grünig, Gabriele , Rischard, Franz, Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Group, PVDOMICS Study, Clinton, Ivor W , Coursen, Julie C , Rosen, Darin T , Barnard, John , Hemnes, Anna , Leopold, Jane A , Horn, Evelyn M , Rosenzweig, Erika B , Frantz, Robert P , Erzurum, Serpil C , King, Wendy , Beck, Gerald J , Hill, Nicholas S , Hassoun, Paul M , Simpson, Catherine E , Mathai, Stephen C , Balasubramanian, Aparna , Mukherjee, Monica , Hsu, Steven , Barnard, John , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , King, Wendy C. , Hassoun, Paul M. , Simpson, Catherine E. , Group, PVDOMICS Study

Mayo Clinic

No container title available | June 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.16.732773 | PMID 42395385 Get It

ABSTRACT Background Pulmonary arterial hypertension (PAH) is characterized by circulating metabolic alterations, but whether these reflect disease-specific metabolic programs or reorganization of normal metabolic architecture, and how they relate to right ventricular-pulmonary vascular function (RV-PV), remains unclear. We hypothesized that the PAH metabolome is organized into biologically coherent, co-regulated metabolic modules whose relationships to RV-PV function would provide insight into known and novel metabolic pathways. Methods We applied weighted gene co-expression network analysis (WGCNA) to untargeted metabolomic data from 412 PAH patients enrolled in the multicenter PVDOMICS study. Module preservation analysis was performed in 85 healthy controls, with external replication in an independent single-center pulmonary hypertension cohort of 89 patients. Results WGCNA identified 16 distinct metabolic modules organized around biologically coherent programs. A coherent fatty acid axis, spanning substrate pools, β-oxidation intermediates, and conjugated fatty acid disposal products, formed a central organizing structure, with downstream fatty acid oxidation modules strongly associated with adverse hemodynamics and worse RV-pulmonary artery (PA) coupling. Acylcholine-enriched and 5α-reduced androgen metabolite modules were associated with favorable hemodynamic indices. Module architecture was largely preserved in healthy controls, with subtle disease-associated modular reorganization, rather than emergence of novel modules, observed in PAH. Core modules were recovered in the replication cohort with conserved hub metabolites. Conclusions These findings establish a systems-level framework demonstrating that PAH involves structured intensification and reorganization of interconnected metabolic programs associated with favorable and adverse RV-PV phenotypes. This work provides new insight into the metabolic architecture underlying PAH and identifies coordinated metabolic pathways linked to pulmonary vascular and right ventricular function.
D28-19 Quality of Life in Pulmonary Arterial Hypertension: A Comparative Analysis of Patients With Insulin Resistance Versus Insulin Sensitivity
Gayner, A, Frantz, R P, Hassoun, P M, Horn, E, Leopold, J, Rischard, F P, Rosenzweig, E B, Hill, N S, Erzurum, S C, Hemnes, A, Al-Naamani, N, Frantz, Robert P. , Hassoun, Paul M. , Horn, E M, Leopold, Jane A. , Rischard, Franz , Rosenzweig, E.B., Hill, N S, Erzurum, S C, Hemnes, A R, Al‐Naamani, Nadine

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 22, 2026 | Volume: 212 | Issue: Supplement_2 | Pages: No page available

10.1093/ajrccm/aamag286.299 Get It

Abstract Introduction Insulin resistance is prevalent in pulmonary arterial hypertension (PAH) and is associated with worse health outcomes. The triglyceride-glucose (TyG) index as a measure of insulin resistance is superior to HOMA-IR in predicting metabolic syndrome. This study utilizes the Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS) data registry to further examine the relationship between TyG index and reported quality of life (QOL) in patients with PAH. Methods 327 patients with a diagnosis of PAH in PVDOMICS were stratified into insulin resistant (IR) (TyG index &gt;8.55) and insulin sensitive (IS) (TyG &lt; 8.55) groups where TyG = (ln[triglyceride*glucose/2]. QOL measures assessed were the Minnesota Living With Heart Failure (MLHF) Physical and Emotional domain surveys, Short Form (36) (SF-36) Physical and Mental Component Health Surveys (PCS and MCS, respectively), and emPHasis-10 (E10). Reported measures between groups were compared using least squares means adjusted for age, sex, fat mass index (FMI), PAH etiology, 6-minute walk distance (6MWD) and NT-pro-brain natriuretic peptide (NTproBNP). Kaplan-Meier curves and Cox proportional hazards models adjusted for these same variables were performed to assess difference in survival between groups. Results 155 patients with PAH (47%) were classified as IR. Patients with IR were more likely to be female (79% vs 69%, p = 0.04), more likely to be non-Hispanic white, and less likely to be non-Hispanic Black (p = 0.045). There were no differences in age or etiology of PAH between groups. Patients with IR had higher body mass index (30.9 vs 27.3 kg/m2, p &lt; 0.001) with higher FMI (16.2 vs 13.2 kg/m2, p &lt; 0.001). Patients with IR were more likely to have diabetes mellitus (24% vs 11%, p = 0.004). Compared to their IS counterparts and after adjusting for possible confounders, patients with IR had higher (worse QOL) MLHF physical domain (p = 0.04), higher (worse QOL) emPhasis-10 scores (p = 0.03), and lower (worse QOL) SF36 physical component scores (p = 0.03) (Figure). IR and IS groups had no significant differences in the MLHF emotional domain and SF36 mental component scores. After multivariable adjustment, there was no difference in survival between groups (HR 0.91, 95% CI 0.56-1.46). Conclusion Patients with PAH and IR had worse QOL compared to their IS counterparts but no difference in survival in this large prospective cohort. This abstract is funded by: This work was supported by the National Institutes of Health grants K23HL 141584, R01 HL173533
Phenotypic Characterization of Unclassified Pulmonary Hypertension
Frantz, Robert P. , Egbe, Alexander C. , Miranda, William R. , Asokan, Aneesh K , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz, Hill, Nicholas S. , Erzurum, Serpil C. , Finet, J. Emanuel , Nishimura, Rick , Frantz, Robert P , Egbe, Alexander C , Miranda, William R , Hassoun, Paul M , Hemnes, Anna , Horn, Evelyn M , Leopold, Jane A , Rosenzweig, Erika B , Hill, Nicholas S , Erzurum, Serpil C , Finet, J Emanuel , Mukherjee, Monica , Tang, W H Wilson , Borlaug, Barry A , Reddy, Yogesh N.V. , Rischard, Franz , Rosenzweig, Erika B. , Mukherjee, Monica , Tang, W.H. Wilson , Nair, K. Sreekumaran , Borlaug, Barry A.

Mayo Clinic

Circulation: Heart Failure | June 19, 2026 | Volume: 19 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.125.014480 | PMID 42318624 Get It

BACKGROUND: Some symptomatic patients manifest pulmonary hypertension (PH), despite normal pulmonary vascular resistance and pulmonary artery wedge pressure—a condition termed unclassified PH. Although hypothesized to reflect increased flow as seen in congenital heart disease, broader clinical implications remain unknown. METHODS: The current analysis included pulmonary vascular disease phenomics participants with either no PH or unclassified PH who underwent dynamic right heart catheterization and transpulmonary metabolomics. In a validation cohort, patients with no PH or unclassified PH underwent exercise right heart catheterization. In exploratory cohorts to understand the impact of increased flow, the prevalence of unclassified PH was assessed in (1) adult congenital heart disease and (2) high output heart failure. RESULTS: The overall prevalence of unclassified PH in pulmonary vascular disease phenomics (n=1046) and the validation cohort (n=1202) was 7.8% (175/2248), which was comparable to the 6.6% (66/1005) prevalence in adult congenital heart disease (n=1005), and lower than high output heart failure (n=159, prevalence 14.5% [23/159]; P =0.006). Increased flow occurred in a minority of unclassified PH from both pulmonary vascular disease phenomics (28%; 15/53) and the validation cohort (11%; 13/122). Unclassified PH (n=53) was associated with greater adiposity, higher heart failure with preserved ejection fraction (HFpEF)–age, body mass index, atrial fibrillation score probability, and more left heart remodeling compared with those with no PH (n=216). Metabolomics revealed lower glycine metabolites in unclassified PH indicative of metabolic dysfunction. Left heart remodeling, quality of life, exercise capacity, and glycine levels were all abnormal in unclassified PH relative to healthy controls (n=96). In the validation cohort, pulmonary artery wedge pressure, pulmonary vascular resistance, and pulmonary artery compliance were subtly abnormal at rest in unclassified PH (n=122) compared with no PH (n=312). With exercise testing, 59% (72/122) with unclassified PH had exertional pulmonary artery wedge pressure elevation consistent with undiagnosed HFpEF. CONCLUSIONS: The presence of PH without obvious cause most often reflects subclinical left heart and metabolic dysfunction consistent with unrecognized early-stage HFpEF. Dynamic provocation during right heart catheterization can unmask unrecognized HFpEF in over half of unclassified PH, which may help guide appropriate initiation of proven HFpEF therapies to improve symptoms and functional status. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02980887.
Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Maclachlan, Kylee , Papadimitriou, Marios , Blaney, Patrick , Baughn, Linda B. , Shekarkhand, Tala , Poos, Alexandra M. , Ziccheddu, Bachisio , Tang, Hongwei , Yan, Huihuang , Diamond, Benjamin , Zhang, Yanming , Cimera, Robert , Hultcrantz, Malin , Mailankody, Sham , Hassoun, Hani , Tan, Carlyn , Brown, Elizabeth , Winterkorn, Lara , Steinsnyder, Zoe , Vaksman, Zalman , Korde, Neha , Weinhold, Niels , Maclachlan, Kylee , Tang, Hongwei , Dogan, Ahmet , Gagler, Dylan , Boyle, Eileen M , Hultcrantz, Malin , Mailankody, Sham , Hassoun, Hani , Shah, Urvi A , Tan, Carlyn R , Brown, Elizabeth E , Winterkorn, Lara , Chu, Timothy , Steinsnyder, Zoe , Vaksman, Zalman , Davies, Faith E , Korde, Neha , Landgren, C Ola , Raab, Marc S , Lesokhin, Alexander M , Robine, Nicolas , Weinhold, Niels , Usmani, Saad , Maura, Francesco , Morgan, Gareth J , Baughn, Linda B , Diamond, Benjamin T , Blaney, Patrick , Poos, Alexandra M. , Doǧan, Ahmet , Boyle, Eileen M. , Shah, Urvi A. , Davies, Faith E. , Landgren, Ola , Raab, Marc S. , Lesokhin, Alexander M. , Usmani, Saad Z. , Maura, Francesco , Morgan, Gareth J.

Mayo Clinic

Blood Cancer Discovery | June 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF17

10.1158/2643-3230.bcd-25-0259 | PMID 42284538 Get It

Abstract Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma. To comprehensively investigate somatic drivers in relation to inherited genetics in multiple myeloma, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing multiple myeloma between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiologic data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop multiple myeloma at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes. Significance: Multiple myeloma is reported to occur at higher rates in individuals who self-identify as non-Hispanic Black. In this large dataset, genomic drivers occur at the same rate among ancestry groups, except for APOBEC mutagenesis. With equivalent therapy, clinical outcomes did not differ for patients grouped by genetic ancestry similarity.
Resolving Diagnostic Discordance in Group 2 Pulmonary Hypertension Through Staged Physiologic Testing: Insights From PVDOMICS
Rischard, Franz , Mendoza, Mateo, Insel, M, Beck, Gerald J. , Erzurum, Serpil C. , Frantz, Robert P. , Finet, J. Emanuel , Hassoun, Paul M. , Hemnes, Anna R. , Hill, Nicholas S. , Group, the PVDOMICS Study, Rischard, Franz P , Horn, Evelyn M , Leopold, Jane A , Mathai, Stephen C , Mehra, Reena , Nishimura, Rick , Rosenzweig, Erika B , Systrom, David M , Tang, W H Wilson , Waxman, Aaron B. , Borlaug, Barry A , Frantz, Robert P , Hemnes, Anna , Hassoun, Paul M , Beck, Gerald J , Finet, J Emanuel , Mendoza, Mateo, Insel, Michael , Horn, Evelyn M. , Leopold, Jane A. , Mathai, Stephen C. , Mehra, Reena , Reddy, Yogesh N.V. , Rosenzweig, Erika B. , Tang, W.H. Wilson , Borlaug, Barry A. , Group, The PVDOMICS Study

Mayo Clinic

No container title available | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.04.26354961 | PMID 42326784 Get It

Abstract Background World Symposium on Pulmonary Hypertension (WSPH) Group 2 pulmonary hypertension (PH) is a clinically integrated phenotype attributed to left heart disease, whereas pre- versus post-capillary classification is operationalized primarily by pulmonary capillary wedge pressure (PCWP). Although current recommendations emphasize contextual interpretation and provocative testing for intermediate PCWP values, the relationship between PCWP-based classification and underlying phenotype has not been systematically evaluated. We aim to quantify phenotype–hemodynamic discordance across the PCWP spectrum and evaluate a staged physiology-guided framework incorporating inhaled nitric oxide (iNO), ventricular geometry, and provocative testing. Methods We studied 1,032 participants from the NHLBI-sponsored PVDOMICS cohort with multidisciplinary adjudicated phenotypes integrating clinical, imaging, physiologic, and hemodynamic data. Stage-specific PCWP thresholds classified pre- versus post-capillary physiology at rest, during iNO, and during provocation (fluid challenge or invasive cardiopulmonary exercise testing [iCPET]). Echocardiographic right ventricular-to-left ventricular (RV/LV) ratio was evaluated as a marker of ventricular interdependence. Restricted cubic spline and staged concordance analyses defined certainty-based PCWP ranges and incremental diagnostic yield. Results Adjudicated Group 2 PH was present in 37.0% of participants. Resting PCWP demonstrated good discrimination (AUC 0.86), but substantial bidirectional phenotype–hemodynamic discordance persisted across intermediate PCWP ranges. At a resting PCWP of 12 mmHg, 25% of participants classified as pre-capillary had adjudicated Group 2 PH, whereas at 18 mmHg, 35% classified as post-capillary remained discordant non–Group 2. Concordance did not approach 90% until PCWP values were <9 mmHg or >24 mmHg. Dynamic testing incrementally improved concordance within these overlap zones. Nearly half of adjudicated Group 2 PH participants (46.5%) were not identified by resting PCWP alone; incorporation of iNO and provocative testing increased cumulative Group 2 identification by 63.4% and improved sensitivity from 79.9% to 83.7%. Model discrimination improved from an AUC of 0.863 to 0.908 (likelihood-ratio P<0.001). iNO increased PCWP in discordant Pre/G2 participants, unmasking latent left-sided limitation, while lowering PCWP in discordant Post/NonG2 participants, consistent with ventricular interdependence. RV/LV ratio ≥0.94 reduced discordant Post/NonG2 classification by 70.5%, and incorporation of PCWP/cardiac output slope improved physiologic specificity during exercise. Conclusions Group 2 PH is a dynamic, load-dependent phenotype inadequately characterized by resting PCWP alone. Intermediate PCWP values represent continuous probabilities of bidirectional discordance rather than discrete diagnostic states. A staged physiology-guided approach integrating iNO, ventricular geometry, and provocative testing improves concordance between hemodynamic classification and clinically integrated phenotype assignment. Clinical Perspective What Is New? In the deeply phenotyped PVDOMICS cohort, resting pulmonary capillary wedge pressure demonstrated good overall discrimination for adjudicated Group 2 (left heart disease) pulmonary hypertension, yet intermediate values frequently either concealed latent left-heart disease or overclassified patients without intrinsic left-heart disease Resting pulmonary capillary wedge pressure should be viewed as a continuous probability signal rather than a binary threshold, allowing additional physiologic testing to be targeted according to the degree of diagnostic uncertainty a clinician is willing to accept. A staged physiology-guided approach incorporating inhaled nitric oxide, ventricular geometry, and provocative testing improved concordance with adjudicated PH category and pre or post-capillary classification. What Are the Clinical Implications? Pre- versus post-capillary classification should be interpreted within the broader clinical and physiologic context rather than relying on a single resting pulmonary capillary wedge pressure threshold. Intermediate pulmonary capillary wedge pressure values should prompt consideration of additional physiologic evaluation, with inhaled nitric oxide providing a practical intermediate step and provocative testing providing the greatest incremental diagnostic yield. Exercise pulmonary capillary wedge pressure/cardiac output slope and markers of ventricular interdependence may provide complementary information for resolving uncertainty when resting and dynamic hemodynamics are discordant.